Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.200
-0.030 (-2.44%)
At close: Nov 13, 2025, 4:00 PM EST
1.210
+0.010 (0.83%)
After-hours: Nov 13, 2025, 7:29 PM EST

Allogene Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202017 - 2019
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
-0.020.10.16114.09-
Upgrade
Revenue Growth (YoY)
--76.84%-39.10%-99.86%--
Upgrade
Cost of Revenue
166.49192.3242.91256.39220.18192.99
Upgrade
Gross Profit
-166.49-192.28-242.82-256.23-106.09-192.99
Upgrade
Selling, General & Admin
58.5365.2171.6779.3174.1165.26
Upgrade
Operating Expenses
58.5365.2171.6779.3174.1165.26
Upgrade
Operating Income
-225.02-257.48-314.49-335.54-180.19-258.24
Upgrade
Interest Expense
-0.84-0.18----
Upgrade
Interest & Investment Income
18.6620.1518.314.571.718.86
Upgrade
Earnings From Equity Investments
--1.69-10.67-12.88-4.09-67.31
Upgrade
Other Non Operating Income (Expenses)
-0.03-0.28-0.163.440.520.31
Upgrade
EBT Excluding Unusual Items
-207.23-239.47-307.02-340.41-182.05-316.38
Upgrade
Gain (Loss) on Sale of Investments
-1.96-1.96-7---
Upgrade
Asset Writedown
-2.38-15.72-13.25---
Upgrade
Pretax Income
-211.57-257.15-327.27-340.41-182.05-316.38
Upgrade
Income Tax Expense
0.440.44----
Upgrade
Net Income
-212.02-257.59-327.27-340.41-182.05-316.38
Upgrade
Net Income to Common
-212.02-257.59-327.27-340.41-182.05-316.38
Upgrade
Shares Outstanding (Basic)
217195157143136120
Upgrade
Shares Outstanding (Diluted)
217195157143136120
Upgrade
Shares Change (YoY)
17.65%24.14%9.63%5.39%12.84%19.11%
Upgrade
EPS (Basic)
-0.98-1.32-2.09-2.38-1.34-2.63
Upgrade
EPS (Diluted)
-0.98-1.32-2.09-2.38-1.34-2.63
Upgrade
Free Cash Flow
-158.99-200.99-239.25-225.71-206.26-181.05
Upgrade
Free Cash Flow Per Share
-0.73-1.03-1.52-1.58-1.52-1.50
Upgrade
Gross Margin
-----92.99%-
Upgrade
Operating Margin
--1170372.73%-331044.21%-215087.18%-157.94%-
Upgrade
Profit Margin
--1170863.64%-344489.47%-218214.10%-159.57%-
Upgrade
Free Cash Flow Margin
--913609.09%-251841.05%-144685.90%-180.79%-
Upgrade
EBITDA
-212.48-243.84-300.29-321.24-169.74-250.81
Upgrade
EBITDA Margin
-----148.78%-
Upgrade
D&A For EBITDA
12.5413.6414.214.310.457.44
Upgrade
EBIT
-225.02-257.48-314.49-335.54-180.19-258.24
Upgrade
EBIT Margin
-----157.94%-
Upgrade
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q